Summary: TRPML1 may play a key role in the neuroprotective and anti-aging effects of rapamycin.
Source: University of Michigan
Easter Island, known as Rapa Nui and famed for its moai statues, gave the world an unexpected medical discovery: the natural product rapamycin.
Discovered in soil bacteria from Rapa Nui, rapamycin has been used for decades as an immunosuppressant. Its applications range from coating coronary stents to preventing organ rejection after transplantation. More recently, researchers have turned their attention to rapamycin’s broader therapeutic potential, investigating its roles in cancer treatment, neuroprotection and the biology of aging.
Rapamycin acts primarily by targeting mTOR, a central regulator of cell growth and metabolism. By inhibiting mTOR, rapamycin suppresses cell growth and proliferation, which makes it a valuable tool in cancer therapies where uncontrolled cell division is a hallmark of disease. Inhibition of mTOR also stimulates autophagy, the cellular recycling program in which lysosomes degrade and repurpose damaged proteins and organelles. Through autophagy, cells can remove harmful debris and reclaim amino acids, lipids and sugars for reuse.
“The main function of the lysosome is to maintain cellular health by degrading harmful material,” said Xiaoli Zhang, a postdoctoral researcher at the University of Michigan Department of Molecular, Cellular and Developmental Biology. “Under stress, autophagy promotes survival by clearing dysfunctional components and supplying essential building blocks like amino acids and lipids.”
Although mTOR has been considered the principal mediator of rapamycin’s effects, the University of Michigan team has identified an additional, direct target: TRPML1, a calcium channel embedded in the lysosomal membrane. TRPML1 (transient receptor potential mucolipin 1) is the primary route by which calcium exits lysosomes, and calcium signaling at the lysosome is vital for the organelle’s function.
Autophagy depends heavily on lysosomal activity, and lysosomal calcium release regulates multiple steps in autophagic processing. Dysfunctional proteins and organelles accumulate with age and especially in neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. Proper TRPML1 function supports lysosomal clearance mechanisms that keep cells healthy and resilient.
“Without this channel, you get neurodegeneration,” said Haoxing Xu, the study’s principal investigator. “If you stimulate the channel, it’s anti-neurodegeneration.”
To probe TRPML1’s role, lead authors Xiaoli Zhang and Wei Chen used lysosome patch-clamp electrophysiology, a technique that records ion channel activity directly from isolated lysosomal membranes. When they applied rapamycin to these lysosomes, the TRPML1 channel opened, demonstrating that rapamycin can activate TRPML1. Crucially, this activation occurred regardless of whether mTOR was active or inhibited, indicating a direct, mTOR-independent action on the lysosomal channel.
Equally important, the researchers showed that rapamycin’s ability to boost autophagy required functional TRPML1. In cells lacking TRPML1, rapamycin and related compounds (rapalogs) no longer triggered the autophagic response. These findings indicate that TRPML1 is essential for the autophagy-enhancing effects of rapamycin in the cellular systems studied.
“We believe lysosomal TRPML1 contributes substantially to the neuroprotective and anti-aging effects of rapamycin,” said Wei Chen. “Identifying TRPML1 as a direct target of rapamycin offers a new avenue for designing next-generation rapamycin-based therapies with improved specificity for neurodegenerative diseases.”
Source:
University of Michigan
Media Contacts:
Morgan Sherburne – University of Michigan
Image Source:
Image credited to University of Michigan.
Original Research (open access):
“Rapamycin directly activates lysosomal mucolipin TRP channels independent of mTOR.” Xiaoli Zhang et al. Published in PLOS Biology. DOI: 10.1371/journal.pbio.3000252
Abstract (summary)
Rapamycin and its derivatives (rapalogs) are being explored clinically for cancer and neurodegenerative diseases, but the full range of their molecular targets is not fully defined. While mTOR is a well-known mediator of rapamycin’s actions, this study identifies TRPML1—the main lysosomal Ca2+ release channel—as a direct and specific target of rapamycin. Patch-clamp experiments on isolated lysosomal membranes revealed that micromolar concentrations of rapamycin and some rapalogs activate TRPML1 directly. Inhibition or genetic loss of mTOR did not replicate this effect, and binding assays indicated direct interaction between rapamycin and TRPML1. In both healthy and disease-model human fibroblasts, rapamycin and rapalogs promoted autophagic flux and induced nuclear translocation of TFEB, a master regulator of lysosomal biogenesis, but these effects were lost in TRPML1-deficient cells or when TRPML1 was pharmacologically blocked. The authors propose that TRPML1-mediated enhancement of autophagy and lysosomal biogenesis may account for a meaningful portion of rapamycin’s neuroprotective and anti-aging benefits.